<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00545818</url>
  </required_header>
  <id_info>
    <org_study_id>YA-SHO-0001</org_study_id>
    <nct_id>NCT00545818</nct_id>
  </id_info>
  <brief_title>Study Comparing OsseoSpeed™ Implants of Two Different Lengths in the Upper and Lower Posterior Jaw</brief_title>
  <official_title>An Open, Prospective, Randomized, Multi-center Study Comparing OsseoSpeed™ Implant 6 mm With OsseoSpeed™ Implant 11 mm in the Posterior Maxilla and Mandible. A 5-year Follow-up Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dentsply Sirona Implants</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dentsply Sirona Implants</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to see if OsseoSpeed™ implant 6 mm long is effective for
      rehabilitation of edentulism and if so, how it compares with OsseoSpeed™ implant 11 mm long.
      The primary hypothesis is that the alteration in bone level is equal in patients randomized
      to 6 mm as to patients randomized to 11 mm implants.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2007</start_date>
  <completion_date type="Actual">May 2016</completion_date>
  <primary_completion_date type="Actual">May 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Radiological Assessments of Marginal Bone Level Alteration</measure>
    <time_frame>Evaluated from implant installation to 5 years follow-up after implant placement</time_frame>
    <description>Marginal Bone Level determined from radiographs and expressed as the difference from a reference point on the implant to the most coronal bone-to-implant contact on the mesial and distal aspect of the implant.
Marginal Bone Level expressed in millimeters at the 5 year follow-up visit compared to values obtained at delivery of temporary restoration i.e. loading (baseline).
Positive value = bone gain, Negative value = bone loss.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Implant Survival</measure>
    <time_frame>Evaluated 5 years after implant placement</time_frame>
    <description>Overall implant survival, measured on implant level</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of the Periimplant Mucosa Condition - By Assessment BoP</measure>
    <time_frame>Measured at the 5-year follow-up visit after loading</time_frame>
    <description>Condition of the periimplant mucosa by assessment of Bleeding on Probing (BoP). Presented as s count of implants that show presence of BoP.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of the Periimplant Mucosa Condition - By Assessment of Change in PPD</measure>
    <time_frame>Evaluated at implant loading and at the 5-year follow-up visit.</time_frame>
    <description>Condition of the periimplant mucosa by assessment of change in probing pocket depth (PPD).
Change in pocket depth expressed in millimeters at the 5-year follow-up visit, compared to values obtained at delivery of permanent restoration, i.e. loading (baseline).
Negative value = increased pocket depth.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Presence of Plaque</measure>
    <time_frame>Evaluated at the 5-year follow-up visit after loading.</time_frame>
    <description>Presence of plaque was evaluated at four surfaces around each study position (mesial, facial, distal and lingual). Plaque was recorded as presence or absence of plaque by visual inspection.
A study position was considered as bleeding &quot;yes&quot; if at least one of the four surfaces around the implant showed presence of bleeding on probing.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">97</enrollment>
  <condition>Jaw, Edentulous, Partially</condition>
  <arm_group>
    <arm_group_label>Group-1, Implant length 6 mm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects treated with OsseoSpeed™ implant, length: 6 mm</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group-2, Implant length 11 mm</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Subjects treated with OsseoSpeed™ implant, length: 11 mm</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>OsseoSpeed™ length 6 mm</intervention_name>
    <description>OsseoSpeed™ dental implant, length: 6 mm</description>
    <arm_group_label>Group-1, Implant length 6 mm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>OsseoSpeed™ length 11 mm</intervention_name>
    <description>OsseoSpeed™ dental implant, length: 11 mm</description>
    <arm_group_label>Group-2, Implant length 11 mm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Provision of informed consent

          -  Aged 20-70 years at enrolment

          -  History of edentulism in the study area of at least four months

          -  Neighboring tooth/teeth to the planned bridge must have natural root(s)

          -  Presence of natural teeth, partial prosthesis and/or implants in the opposite jaw in
             contact with the planned bridge.

          -  Deemed by the investigator to have a bone height of at least 11 mm and a bone width of
             minimum 6 mm

          -  Deemed by the investigator as likely to present an initially stable implant situation

        Exclusion Criteria:

          -  Unlikely to be able to comply with study procedures, as judged by the investigator

          -  Earlier graft procedures in the study area

          -  Uncontrolled pathologic processes in the oral cavity

          -  Known or suspected current malignancy

          -  History of radiation therapy in the head and neck region

          -  History of chemotherapy within 5 years prior to surgery

          -  Systemic or local disease or condition that could compromise post-operative healing
             and/or osseointegration

          -  Uncontrolled diabetes mellitus

          -  Corticosteroids or any other medication that could influence post-operative healing
             and/or osseointegration

          -  Smoking more than 10 cigarettes/day

          -  Present alcohol and/or drug abuse

          -  Involvement in the planning and conduct of the study (applies to both Astra Tech staff
             and staff at the study site)

          -  Previous enrolment in the present study.

          -  Severe non-compliance to protocol as judged by the investigator and/or Astra Tech

          -  Simultaneous participation in another clinical study, or participation in a clinical
             study during the last 6 months
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anna-Karin Lundgren</last_name>
    <role>Study Director</role>
    <affiliation>Direktor Clinical Research, Dentsply Sirona Implants, Mölndal, SWEDEN</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>USC School of Dentistry</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90089-0641</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The University of Iowa, College of Dentistry</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242-1010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>School of Dental Science, University of Melbourne</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3010</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praktijk De Mondhoek</name>
      <address>
        <city>Apeldoorn</city>
        <zip>7315</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dept. of Parodontology, Göteborg University</name>
      <address>
        <city>Göteborg</city>
        <zip>SE 405 30</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>King's College London Dental Institute at Guy's King's and St Thomas' Hospitals</name>
      <address>
        <city>London</city>
        <zip>SE1 9RT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Netherlands</country>
    <country>Sweden</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Guljé F, Abrahamsson I, Chen S, Stanford C, Zadeh H, Palmer R. Implants of 6 mm vs. 11 mm lengths in the posterior maxilla and mandible: a 1-year multicenter randomized controlled trial. Clin Oral Implants Res. 2013 Dec;24(12):1325-31. doi: 10.1111/clr.12001. Epub 2012 Sep 3.</citation>
    <PMID>22938573</PMID>
  </results_reference>
  <results_reference>
    <citation>Zadeh HH, Guljé F, Palmer PJ, Abrahamsson I, Chen S, Mahallati R, Stanford CM. Marginal bone level and survival of short and standard-length implants after 3 years: An Open Multi-Center Randomized Controlled Clinical Trial. Clin Oral Implants Res. 2018 Aug;29(8):894-906. doi: 10.1111/clr.13341. Epub 2018 Jul 12.</citation>
    <PMID>30003598</PMID>
  </results_reference>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>October 16, 2007</study_first_submitted>
  <study_first_submitted_qc>October 16, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 17, 2007</study_first_posted>
  <results_first_submitted>April 14, 2020</results_first_submitted>
  <results_first_submitted_qc>May 7, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">May 19, 2020</results_first_posted>
  <last_update_submitted>May 7, 2020</last_update_submitted>
  <last_update_submitted_qc>May 7, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 19, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Jaw, Edentulous</mesh_term>
    <mesh_term>Jaw, Edentulous, Partially</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>97 subjects were enrolled in the study (singed informed consent).Two of those subjects fulfilled exclusion criteria and were removed from the study population before randomization.
As a consequence a total of 95 subjects were randomised (assigned to groups) and received study treatment.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Group-1, Implant Length 6 mm</title>
          <description>Subjects treated with OsseoSpeed™ implant, length: 6 mm</description>
        </group>
        <group group_id="P2">
          <title>Group-2, Implant Length 11 mm</title>
          <description>Subjects treated with OsseoSpeed™ implant, length: 11 mm</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="49"/>
                <participants group_id="P2" count="46"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="46"/>
                <participants group_id="P2" count="39"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Group-1, Implant Length 6 mm</title>
          <description>Subjects treated with OsseoSpeed™ implant, length: 6 mm</description>
        </group>
        <group group_id="B2">
          <title>Group-2, Implant Length 11 mm</title>
          <description>Subjects treated with OsseoSpeed™ implant, length: 11 mm</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="49"/>
            <count group_id="B2" value="46"/>
            <count group_id="B3" value="95"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="54.8" spread="9.39"/>
                    <measurement group_id="B2" value="54.1" spread="10.04"/>
                    <measurement group_id="B3" value="54.5" spread="9.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="47"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="27"/>
                    <measurement group_id="B3" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Sweden</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Netherlands</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United Kingdom</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Australia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Radiological Assessments of Marginal Bone Level Alteration</title>
        <description>Marginal Bone Level determined from radiographs and expressed as the difference from a reference point on the implant to the most coronal bone-to-implant contact on the mesial and distal aspect of the implant.
Marginal Bone Level expressed in millimeters at the 5 year follow-up visit compared to values obtained at delivery of temporary restoration i.e. loading (baseline).
Positive value = bone gain, Negative value = bone loss.</description>
        <time_frame>Evaluated from implant installation to 5 years follow-up after implant placement</time_frame>
        <population>A total of 85 subjects (184 implants) completed the study. For a total of 10 implants (in 5 subjects) the quality of the radiographs were not sufficient for reading, giving a total of 80 subjects (174 implants) for the analysis of MBL change.</population>
        <group_list>
          <group group_id="O1">
            <title>Group-1, Implant Length 6 mm</title>
            <description>Subjects treated with OsseoSpeed™ implant, length: 6 mm</description>
          </group>
          <group group_id="O2">
            <title>Group-2, Implant Length 11 mm</title>
            <description>Subjects treated with OsseoSpeed™ implant, length: 11 mm</description>
          </group>
        </group_list>
        <measure>
          <title>Radiological Assessments of Marginal Bone Level Alteration</title>
          <description>Marginal Bone Level determined from radiographs and expressed as the difference from a reference point on the implant to the most coronal bone-to-implant contact on the mesial and distal aspect of the implant.
Marginal Bone Level expressed in millimeters at the 5 year follow-up visit compared to values obtained at delivery of temporary restoration i.e. loading (baseline).
Positive value = bone gain, Negative value = bone loss.</description>
          <population>A total of 85 subjects (184 implants) completed the study. For a total of 10 implants (in 5 subjects) the quality of the radiographs were not sufficient for reading, giving a total of 80 subjects (174 implants) for the analysis of MBL change.</population>
          <units>millimeter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>Implants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
                <count group_id="O2" value="36"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Implants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="94"/>
                <count group_id="O2" value="80"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.02" spread="0.52"/>
                    <measurement group_id="O2" value="-0.18" spread="1.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Implant Survival</title>
        <description>Overall implant survival, measured on implant level</description>
        <time_frame>Evaluated 5 years after implant placement</time_frame>
        <population>Group-1. A total of 49 subjects (108 positions) underwent surgery. Three positions were not implanted due to complications during surgery. Giving a total 105 implants installed.
Group-2. A total of 46 subjects (101 positions) underwent surgery. Giving a total of 101 implants installed.</population>
        <group_list>
          <group group_id="O1">
            <title>Group-1, Implant Length 6 mm</title>
            <description>Subjects treated with OsseoSpeed™ implant, length: 6 mm</description>
          </group>
          <group group_id="O2">
            <title>Group-2, Implant Length 11 mm</title>
            <description>Subjects treated with OsseoSpeed™ implant, length: 11 mm</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Implant Survival</title>
          <description>Overall implant survival, measured on implant level</description>
          <population>Group-1. A total of 49 subjects (108 positions) underwent surgery. Three positions were not implanted due to complications during surgery. Giving a total 105 implants installed.
Group-2. A total of 46 subjects (101 positions) underwent surgery. Giving a total of 101 implants installed.</population>
          <units>implants</units>
          <param>Count of Units</param>
          <units_analyzed>implants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
                <count group_id="O2" value="46"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>implants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="105"/>
                <count group_id="O2" value="101"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="101"/>
                    <measurement group_id="O2" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Evaluation of the Periimplant Mucosa Condition - By Assessment BoP</title>
        <description>Condition of the periimplant mucosa by assessment of Bleeding on Probing (BoP). Presented as s count of implants that show presence of BoP.</description>
        <time_frame>Measured at the 5-year follow-up visit after loading</time_frame>
        <population>A total of 85 subjects (184 implants) completed the 5-year follow-up visit. All included in the assessment of BoP.</population>
        <group_list>
          <group group_id="O1">
            <title>Group-1, Implant Length 6 mm</title>
            <description>Subjects treated with OsseoSpeed™ implant, length: 6 mm</description>
          </group>
          <group group_id="O2">
            <title>Group-2, Implant Length 11 mm</title>
            <description>Subjects treated with OsseoSpeed™ implant, length: 11 mm</description>
          </group>
        </group_list>
        <measure>
          <title>Evaluation of the Periimplant Mucosa Condition - By Assessment BoP</title>
          <description>Condition of the periimplant mucosa by assessment of Bleeding on Probing (BoP). Presented as s count of implants that show presence of BoP.</description>
          <population>A total of 85 subjects (184 implants) completed the 5-year follow-up visit. All included in the assessment of BoP.</population>
          <units>implants</units>
          <param>Count of Units</param>
          <units_analyzed>implants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
                <count group_id="O2" value="39"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>implants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="98"/>
                <count group_id="O2" value="86"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43"/>
                    <measurement group_id="O2" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Evaluation of the Periimplant Mucosa Condition - By Assessment of Change in PPD</title>
        <description>Condition of the periimplant mucosa by assessment of change in probing pocket depth (PPD).
Change in pocket depth expressed in millimeters at the 5-year follow-up visit, compared to values obtained at delivery of permanent restoration, i.e. loading (baseline).
Negative value = increased pocket depth.</description>
        <time_frame>Evaluated at implant loading and at the 5-year follow-up visit.</time_frame>
        <population>A total of 85 subjects (184 implants) completed the 5-year follow-up visit. Group-1. For 3 subjects (7 implants) the radiographs were not possible to evaluate, giving a total of 43 subjects (91 implants) being available for evaluation of change in PPD.
Group-2. All radiographs readable, giving 39 subjects (86 positions) for the evaluation.</population>
        <group_list>
          <group group_id="O1">
            <title>Group-1, Implant Length 6 mm</title>
            <description>Subjects treated with OsseoSpeed™ implant, length: 6 mm</description>
          </group>
          <group group_id="O2">
            <title>Group-2, Implant Length 11 mm</title>
            <description>Subjects treated with OsseoSpeed™ implant, length: 11 mm</description>
          </group>
        </group_list>
        <measure>
          <title>Evaluation of the Periimplant Mucosa Condition - By Assessment of Change in PPD</title>
          <description>Condition of the periimplant mucosa by assessment of change in probing pocket depth (PPD).
Change in pocket depth expressed in millimeters at the 5-year follow-up visit, compared to values obtained at delivery of permanent restoration, i.e. loading (baseline).
Negative value = increased pocket depth.</description>
          <population>A total of 85 subjects (184 implants) completed the 5-year follow-up visit. Group-1. For 3 subjects (7 implants) the radiographs were not possible to evaluate, giving a total of 43 subjects (91 implants) being available for evaluation of change in PPD.
Group-2. All radiographs readable, giving 39 subjects (86 positions) for the evaluation.</population>
          <units>millimeters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>implants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="43"/>
                <count group_id="O2" value="39"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>implants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="91"/>
                <count group_id="O2" value="86"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.57" spread="0.92"/>
                    <measurement group_id="O2" value="-1.11" spread="1.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Presence of Plaque</title>
        <description>Presence of plaque was evaluated at four surfaces around each study position (mesial, facial, distal and lingual). Plaque was recorded as presence or absence of plaque by visual inspection.
A study position was considered as bleeding &quot;yes&quot; if at least one of the four surfaces around the implant showed presence of bleeding on probing.</description>
        <time_frame>Evaluated at the 5-year follow-up visit after loading.</time_frame>
        <population>A total of 85 subjects (184 implants) completed the 5-year follow-up visit. All included in the assessment of presence of plaque.</population>
        <group_list>
          <group group_id="O1">
            <title>Group-1, Implant Length 6 mm</title>
            <description>Subjects treated with OsseoSpeed™ implant, length: 6 mm</description>
          </group>
          <group group_id="O2">
            <title>Group-2, Implant Length 11 mm</title>
            <description>Subjects treated with OsseoSpeed™ implant, length: 11 mm</description>
          </group>
        </group_list>
        <measure>
          <title>Presence of Plaque</title>
          <description>Presence of plaque was evaluated at four surfaces around each study position (mesial, facial, distal and lingual). Plaque was recorded as presence or absence of plaque by visual inspection.
A study position was considered as bleeding &quot;yes&quot; if at least one of the four surfaces around the implant showed presence of bleeding on probing.</description>
          <population>A total of 85 subjects (184 implants) completed the 5-year follow-up visit. All included in the assessment of presence of plaque.</population>
          <units>implants</units>
          <param>Count of Units</param>
          <units_analyzed>implants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
                <count group_id="O2" value="39"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>implants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="98"/>
                <count group_id="O2" value="86"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>5 years</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Group-1, Implant Length 6 mm</title>
          <description>Subjects treated with OsseoSpeed™ implant, length: 6 mm</description>
        </group>
        <group group_id="E2">
          <title>Group-2, Implant Length 11 mm</title>
          <description>Subjects treated with OsseoSpeed™ implant, length: 11 mm</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Undefined heart problems</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Eye cancer (basal cell carcinoma)</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Gallbladder removed</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Liver cancer</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Right hip replacement, post-op infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Armpit abscess due to spider bite.</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Bilateral toe infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Osteopaenia, trauma - fractured toes</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Hip function failure</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Broken pelvis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Hip fracture due to car accident</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Product Issues</title>
            <event_list>
              <event>
                <sub_title>Failure knee-prosthesis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Insufficient renal function (30%)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Ovarian cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pneumonitis - Non Hodgkin disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Squamous cell skin cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Arteriosclerosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Product Issues</title>
            <event_list>
              <event>
                <sub_title>Study implant failure</sub_title>
                <description>Study implant failure (including implant mobility, excessive bone loss around implant and, implant related pain)</description>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="49"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Bridge screw loosening</sub_title>
                <description>Loosening of the screw attaching the restoration (the bridge) to the implant abutment.</description>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="49"/>
                <counts group_id="E2" events="10" subjects_affected="5" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Abutment fracture</sub_title>
                <description>Fracture of the abutment connecting the implant with the restoration</description>
                <counts group_id="E1" events="4" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Fracture of temporary bridge</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="49"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Manager Global Clinical Research</name_or_title>
      <organization>Dentsply Sirona Implants, Mölndal, SWEDEN</organization>
      <phone>0046313763500</phone>
      <email>ClinicalResearchMolndal@dentsplysirona.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

